150 related articles for article (PubMed ID: 38140901)
1. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
2. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
3. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use.
Fung V; Price M; Cheng D; Patel TA; Yang Z; Hsu J; Alegria M; Newhouse JP
JAMA Health Forum; 2024 Feb; 5(2):e235152. PubMed ID: 38306091
[TBL] [Abstract][Full Text] [Related]
5. Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia.
Doshi JA; Li P; Geng Z; Seo S; Patel C; Benson C
Psychiatr Serv; 2024 Apr; 75(4):333-341. PubMed ID: 37960866
[TBL] [Abstract][Full Text] [Related]
6. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
7. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
8. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
9. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
10. Effects of an out-of-pocket maximum in Medicare Part D.
Parasrampuria S; Anderson GF
Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
[TBL] [Abstract][Full Text] [Related]
11. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
[TBL] [Abstract][Full Text] [Related]
12. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
13. Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance.
Parasrampuria S; Sen AP; Anderson GF
Am J Manag Care; 2020 Sep; 26(9):388-394. PubMed ID: 32930551
[TBL] [Abstract][Full Text] [Related]
14. Cognition and take-up of subsidized drug benefits by Medicare beneficiaries.
Kuye IO; Frank RG; McWilliams JM
JAMA Intern Med; 2013 Jun; 173(12):1100-7. PubMed ID: 23649604
[TBL] [Abstract][Full Text] [Related]
15. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
17. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
18. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
19. In-gap discounts in Medicare Part D and specialty drug use.
Jung J; Xu WY; Cheong C
Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
[TBL] [Abstract][Full Text] [Related]
20. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
